Loading stock data…
Kenvue Inc (KVUE)
$18.74-0.21 (-1.11%)
Pre-Market$18.63-0.11 (-0.59%)· Last close Sep 4
Kenvue Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kenvue Inc. in the Consumer Defensive sector is trading at $18.74 with a market capitalization of $35.5B. Wall Street consensus targets $19.50 (12 analysts), implying a +4.1% move over the next 12 months. The stock is currently 7% below its 52-week high of $20.13, remaining 6.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.96B↑ | $3.91B↑ | $3.78B↑ | $3.76B↓ | $3.84B |
| Gross Profit | $2.30B | $2.30B↑ | $2.14B↓ | $2.23B↓ | $2.26B |
| Operating Income | $758.00M↓ | $838.00M↑ | $632.00M↓ | $713.00M↓ | $752.00M |
| Net Income | $456.00M↓ | $474.00M↑ | $330.00M↓ | $398.00M↓ | $420.00M |
Peer Comparison
Fundamentals
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Healt...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$35.48B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
3.36%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.29%
Volume
Today's trading volume
26.75M
Recent News
Can Kimberly-Clark Turn its $40 Billion Kenvue Bet into $2.1 Billion in Savings?
Kimberly-Clark Corporation’s (NASDAQ:KMB) proposed $40 billion takeover of Kenvue has entered another stage of regulatory review. Documents on the European Commission’s website show that Kimberly-Clark has requested EU permission to complete the transaction, which was first announced in November 2025. The deal would combine Kimberly-Clark (NASDAQ:KMB) with a large portfolio of consumer-health brands, including Tylenol, […]
Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead
KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.
Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth?
Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.
This Dividend King Just Offered a Buy-the-Dip Opportunity
Deal skepticism and litigation fears still weigh on this consumer staples stalwart.
Kimberly Clark (KMB) Names New Legal Chief As Kenvue Deal Puts Valuation In Focus
Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...